Salih Aksu

Salih Aksu

Auto-generated profile, based on publicly available information

Salih Aksu

Department of Hematology, Faculty of Medicine, Hacettepe University, Ankara, Turkey

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 June 2020 in TURKISH JOURNAL OF MEDICAL SCIENCES
Verified
Journal Article
Open access
HGHakan Göker
Hakan Göker
EAElifcan Aladag
Elifcan Aladag
HDHaluk Demi̇rOğlu
Haluk Demi̇rOğlu
CACaglayan Merve Ayaz
Caglayan Merve Ayaz
YBYahya Büyükaşik
Yahya Büyükaşik
SUSerhat Unal
Serhat Unal
COVID-19 (Coronavirus Disease of 2019) is an infectious disease outbreak later on declared as a pandemic, caused by the SARS-CoV-2 (severe acute respiratory syndrome coronavirus-2). It spreads very rapidly and can result in severe acute respiratory failure. The clinical studies have shown that advanced age and chronic diseases increase the risk of infection. However, influence of the blood groups on COVID-19 infection and its outcome remains to be confirmed. The aim of this study is to investigate whether there exists a relationship between the blood groups of the patients and risk of SARS-CoV-2 infection and the clinical outcomes in COVID-19 patients. 186 patients with PCR confirmed diagnosis of COVID-19 were included in this study. Age, gender, blood groups, comorbidities, need for intubation and intensive care unit follow up and mortalities of the patients were analyzed retrospectively. 1881 healthy individuals, who presented to the Hacettepe University Blood Bank served as the controls. The most frequently detected blood group was blood group A (57%) amongst the COVID-19 patients. This was followed by the blood group O (24.8%). The blood group types did not affect the clinical outcomes. Blood group A was statistically significantly more frequent among those infected with COVID-19 compared to controls (57% vs 38%, p <0.001; OR: 2.1). On the other hand, the frequency of blood group O was significantly lower in the COVID-19 patients, compared to the control group (24.8% vs 37.2%, p: 0.001; OR: 1.8). The results of the present study suggest that while the blood group A might have a role in increased susceptibility to the COVID-19 infection, the blood group O might be somewhat protective. However, once infected, blood group type does not seem to influence clinical outcome.

17 December 2020 in TURKISH JOURNAL OF MEDICAL SCIENCES
Verified
Journal Article
Open access
EAElifcan Aladag
Elifcan Aladag
HDHaluk Demi̇rOğlu
Haluk Demi̇rOğlu
YBYahya Büyükaşik
Yahya Büyükaşik
MTMehmet Turgut
Mehmet Turgut
SASalih Aksu
Salih Aksu
HGHakan Göker
Hakan Göker
High-dose melphalan and autologous hematopoietic stem cell transplantation (AHSCT) is the standard treatment strategy in Multiple Myeloma (MM) patients who are eligible for AHSCT. The recommended dose of CD34+ hematopoietic progenitor cells (HPC) for adequate engraftment is above 2 x 106/kg.. The aim of this study is to evaluate the relationship between CD34+ HPC dose and the survival in MM patients who underwent AHSCT at our tertiary care center. 271 MM patients, who underwent AHSCT between 2003-2019, were enrolled in this study. Clinical characteristic of patients, disease status pre-AHSCT, re-infused CD34+ cell doses, neutrophil and platelet engraftment days were recorded, retrospectively. The patients were divided into two groups according to whether re-infused CD 34+ HPC dose were < 5 x 106 /kg or ? 5 x 106 /kg. The groups were compared in terms of engraftment and overall survival times. The median age of all patients was 54.8 (33 - 76) years. The median CD34+ HPC dose infused was 5.94 x 106/kg (1.47 - 59.5 x 106/kg). The median follow-up period was 54 months (4-211). The median overall survival of all patients was 103 months (11-144). Median neutrophil and platelet engraftment time was 10 (8-24) and 11 (7-40) days, respectively. < 5 x 106/kg and ? 5 x 106/kg CD34+ HPC were reinfused 38,1% and 61.9% of the patients, respectively. There was a negative significant correlation between reinfused CD34+ cell level and neutrophil/platelet engraftment times (r: -0.32, p= <0.001; r: -0.27, p= <0.001, respectively). The median overall survival times were observed as 103 months (11-144) and 145 months (123-166) for patients who were administered ? 5 x 106/kg and < 5 x 106/kg of CD34+ HPC, respectively (p= 0.009). The increased amount of CD34+ autologous hematopoietic stem cell dose after high dose melphalan chemotherapy in MM patients shortens platelet and neutrophil engraftment time and increases overall survival. Early platelet engraftment and administration of CD34+ HPC count ? 5 x 106/kg can be considered as predictors of a better survival in patients.

3 May 2019 in Turkish Journal of Hematology
Verified
Journal Article
Open access
RÇRafiye Çiftçiler
Rafiye Çiftçiler
HGHakan Göker
Hakan Göker
HDHaluk Demiroğlu
Haluk Demiroğlu
EAElifcan Aladag
Elifcan Aladag
SASalih Aksu
Salih Aksu
YBYahya Büyükaşık
Yahya Büyükaşık
Objective: Allogeneic hematopoietic stem cell transplantation (HSCT) is an effective treatment modality for a variety of malignant and non-malignant hematologic disorders. Myeloablative conditioning (MAC) and reduced-intensity conditioning (RIC) regimens could have different clinical outcomes. This purpose of this study was to assess the long-term outcome of MAC versus RIC regimens in patients with acute myeloid leukemia (AML) undergoing allogeneic HSCT. Materials and Methods: We retrospectively compared long-term outcomes with MAC and RIC regimens in patients with AML who underwent allo-HSCT at our tertiary transplantation center. Results: We analyzed survival outcomes after MAC-HSCT versus RIC-HSCT among 107 adult patients with AML diagnosed from 2001 through 2017. Of those, 44 patients underwent a MAC regimen, whereas 63 patients received a RIC regimen. The median follow-up time was 37 months (range: 6-210) for the entire group. The 3-year overall survival (OS) for RIC and MAC patients was 67% and 60%, respectively (p> 0.05). The 3-year progression-free survival (PFS) for RIC and MAC patients was 88% and 77%. In multivariate analysis, the type of conditioning regimen (RIC vs. MAC) did not influence PFS (p=0.24). Acute graft-versus-host disease (GVHD) was seen in five of the RIC patients and 9 of the MAC patients. Chronic GVHD was seen in 16 of the RIC patients and 6 of the MAC patients. There was no significant difference between the two groups in terms of acute GVHD (p=0.089), but there was a significant difference between the two groups in terms of chronic GVHD (p=0.03). Conclusion: This retrospective analysis confirmed that MAC and RIC regimens had a consistently equivalent rate of OS and PFS in AML patients who underwent allo-HSCT. The choice of MAC versus RIC conditioning regimen might be decided on the basis of patient and disease characteristics.

30 August 2021 in TURKISH JOURNAL OF MEDICAL SCIENCES
Verified
Journal Article
Open access
AKAyşe KARATAŞ
Ayşe KARATAŞ
UMUmit Yavuz Malkan
Umit Yavuz Malkan
MVMustafa Velet
Mustafa Velet
HDHaluk Demi̇roğlu
Haluk Demi̇roğlu
YBYahya Büyükaşik
Yahya Büyükaşik
HGHakan Göker
Hakan Göker
The disease caused by SARS-CoV-2 was named as COVID-19. There is as yet insufficient information about the effects of HSCT on the clinical course of COVID-19. In the present study, we aimed to investigate the clinical course of COVID-19 in patients who had undergone HSCT. We analyzed baseline characteristics, clinical course and findings of COVID-19, hospitalization and death rates, overall survival and case fatality rates of HSCT recipients diagnosed with COVID-19 retrospectively. 57.6% of the patients underwent AHSCT, and 42.4% underwent allo-HSCT. 60.6%, 27.3%, and 12.1% of the patients had mild, moderate and severe COVID-19 or critical illness, respectively. 45.5% were hospitalized, and 12.1% required intensive care. 9.1% necessitated invasive mechanical ventilation. The total CFR was 9.1% in HSCT recipients, 22.2% in patients with active hematologic malignancy and 4.2% in patients without active hematologic malignancy. It can be concluded that mortality of HSCT recipients is lower in patients whose primary disease is in remission compared to ones that are not in remission. Further studies with larger group patients are needed in order to delineate the effects of COVID-19 on HSCT patients.

11 February 2019 in TURKISH JOURNAL OF MEDICAL SCIENCES
Verified
Journal Article
Open access
RÇRafiye Çi̇fTçi̇lEr
Rafiye Çi̇fTçi̇lEr
SASalih Aksu
Salih Aksu
NFNeslihan Di̇kMenoğlu Falkmarken
Neslihan Di̇kMenoğlu Falkmarken
Ankaferd hemostat (ABS; Ankaferd blood stopper, İstanbul, Turkey) is a prohemostatic agent affecting erythrocytes. The hemostatic action of ABS depends upon fibrinogen gamma chain, prothrombin, and red blood cells. The aim of this study was to assess the effects of ABS on erythrocyte aggregation via hemorheological analyses. To measure erythrocyte aggregation, blood samples were obtained from healthy, nonsmoker volunteers who had not taken any medication in the previous 10 days. One mL of blood was placed into the laser-assisted optical rotational cell analyzer (LORCA), into the chamber formed by the gap between two concentric glass cylinders. The solution prepared with ABS and saline was added to blood in incremental amounts of 10 μL, 20 μL, 30 μL, 40 μL, 50 μL, 60 μL, 70 μL, and 100 μL. Erythrocyte aggregation was determined by laser-assisted optical rotational cell analyzer at 37 °C AMPwas found to be 17.7 ± 2.1 au in the blood without ABS, whereas it was lower in the blood with ABS. AMP was 16.0 ± 3.3 in the ABS-added blood group. RBC aggregates did not form faster when cells contacted ABS. The t t½ value was 4.6 ± 2.6 in the ABS-added blood group and 1.9 ± 0.20 in the control group. Aggregation was faster in the control group (P = 0.03). AI, which is a combination of AMP and t½, was lowered in the ABS group (48.7 ± 12.3) compared to the control group (65.8 ± 1.6) (P = 0.02). It was notable that the γIsc max (sec-1) value of the control was higher (200 ± 106) than the ABS-added blood group (141 ± 51.0). ABS has antierythroid aggregation effect. ABS inhibits pathological aggregation of red blood cells. Antithrombotic clinical effects of ABS may be ascribed to the antierythroid aggregan actions of the drug.

24 October 2019 in TURKISH JOURNAL OF MEDICAL SCIENCES
Verified
Journal Article
Open access
EAElifcan Aladag
Elifcan Aladag
ESEmine Arzu Sağlam
Emine Arzu Sağlam
SASalih Aksu
Salih Aksu
HDHaluk Demiroğlu
Haluk Demiroğlu
NSNilgün Sayinalp
Nilgün Sayinalp
YBYahya Büyükaşik
Yahya Büyükaşik
Background/aim: Polycythemia Vera (PV) is a myeloproliferative disorder characterized by overproduction of morphologically normal red blood cells (RBCs), granulocytes, and platelets, a phenotype that is caused by a mutation (V617F) in Janus kinase 2 (JAK2). However, JAK2 V617F is also found in approximately 50% of patients with essential thrombocytosis and primary myelofibrosis, rendering its presence nonspecific as a diagnostic test. An increased red cell mass is a major criterion for the diagnosis of PV according to World Health Organization (WHO) 2016 criteria. High hemoglobin (Hgb) or Hematocrit (Hct) are universally used as indicators of an increased red cell mass for the diagnosis of PV. However, conditions such as iron deficiency (ID) with decreased mean cell volume may mask the diagnosis due to nonelevated Hct level. The aim of this study was to investigate the clinical characteristics of the patients with unclassifiable non-CML classical myeloproliferative disease with microcytosis (MPD/M) and nonelevated Hgb and Hct levels at diagnosis and to determine if some of these cases could be real PV cases masked due to ID-related microcytosis. Materials and methods: There were 23 MPD/M cases among 208 non-CML classical MPD cases (11%). Among 22 patients who had adequate test results related to the cause of microcytosis, ID and beta- thalassemia trait (TT) were the apparent causes of microcytosis in 15 and 1 cases, respectively. Results: Clinicopathological correlations revealed consistently positive JAK2 V617F mutation status (20/20, 100%), frequently elevated RBC count (17/23, 73.9%), and PV-compatible bone marrow findings (10/12, 83.3%). These findings are compatible with PV instead of essential thrombocytopenia or primary myelofibrosis. in spite of frequent cytoreductive treatment, 3 patients developed increased Hgb/Htc levels during median 58.2 (279-63) months' follow-up. Conclusion: These data show that the majority of MPD/M cases are PV patients masked due to ID-related microcytosis.